Stifel Financial Corp Halozyme Therapeutics, Inc. Transaction History
Stifel Financial Corp
- $93.7 Billion
- Q4 2024
A detailed history of Stifel Financial Corp transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Stifel Financial Corp holds 30,768 shares of HALO stock, worth $1.8 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
30,768
Previous 17,121
79.71%
Holding current value
$1.8 Million
Previous $979,000
50.26%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding HALO
# of Institutions
535Shares Held
122MCall Options Held
413KPut Options Held
154K-
Black Rock Inc. New York, NY17.6MShares$1.03 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.3MShares$778 Million0.01% of portfolio
-
State Street Corp Boston, MA7.18MShares$421 Million0.01% of portfolio
-
Snyder Capital Management L P San Francisco, CA4.06MShares$238 Million5.07% of portfolio
-
Bank Of America Corp Charlotte, NC3.45MShares$202 Million0.01% of portfolio
About HALOZYME THERAPEUTICS, INC.
- Ticker HALO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 139,288,992
- Market Cap $8.16B
- Description
- Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...